|
|
|
|
Chugai Pharma seeks Japanese additional approval for anti-cancer agents Herceptin & Xeloda
Chugai Pharmaceutical Co, Ltd announced that it filed an application with the Japanese Ministry of Health, Labour and Welfare, seeking additional approval of combination therapy with trastuzumab (genetical recombination), a humanized monoclonal antibody (brand...
|
|
|
::: Anti-Cancer Agents, Herceptin and Xeloda Filed for HER2-positive Advanced or Recurrent Gastric Cancer
(Tokyo) - Chugai Pharmaceutical Co., Ltd.[Main Office: Chuo-ku, Tokyo. President: Osamu Nagayama (hereafter 'Chugai')] announced today that it filed an application with the Japanese Ministry of Health, Labour and Welfare, seeking additional approval of...
|
|
|
Late-Stage Cancer Misses Could Mean Advantage for Competitors
A double dose of disappointing Phase III data late last week from Pfizer Inc.and Genentech Inc. marked small setbacks for the big drugmakers but could be good news in the long run for their smaller biotech competitors. The failure of New York-based...
|
|
|
Late-Stage Cancer Misses Could Mean Advantage for Competitors
A double dose of disappointing Phase III data late last week from Pfizer Inc.and Genentech Inc. marked small setbacks for the big drugmakers but could be good news in the long run for their smaller biotech competitors. The failure of New York-based...
|
|
|
Pfizer's 3 Points of Failure
Pfizer (NYSE: PFE) is not having a good March.Last week, its Cinderella story, Alzheimer's drug Dimebon, which it licensed from Medivation (Nasdaq: MDVN), failed its first phase 3 trial for effectiveness. And then yesterday, the clinical-trial (March)...
|
|
|
Genentech says Avastin trial did not meet goal
NEW YORK -- Roche's efforts to win new marketing approvals for a cancer treatment candidate hit another stumbling block Friday as the Swiss drugmaker said Avastin did not improve survival among prostate cancer patients in a clinical study.Roche's Genentech...
|
|
|
Genentech says cancer drug Avastin did not improve prostate cancer patient survival in study
NEW YORK Roche's efforts to win new marketing approvals for a cancer treatment candidate hit another stumbling block Friday as the Swiss drugmaker said Avastin did not improve survival among prostate cancer patients in a clinical study.Roche's Genentech...
|
|
|
Genentech says Avastin trial did not meet goal
NEW YORK (AP) -- Roche's efforts to win new marketing approvals for a cancer treatment candidate hit another stumbling block Friday as the Swiss drugmaker said Avastin did not improve survival among prostate cancer patients in a clinical study.Roche's Genentech...
|
|
|
Is there a clear role for hormonal therapy in metastatic breast cancer?
Eric P.Winer, MD Reporting from the MBCC, ONCOLOGY spoke with Eric P. Winer, MD, Director, Breast Oncology Center; Chief, Division of Women's Cancers; Thompson Senior Investigator in Breast Cancer Research, Dana-Farber Cancer Institute. At this years...
|
|
|
Lancet: New rectal cancer treatment yields promising outcomes
FURTHER READING Organization Canberra Hospital Person Topic cardiotoxic event chemoradiation chemoradiotherapy chemotherapy mesorectal excision MRI rectal cancer surgical resection Portals For patients with high-risk, potentially , therapy with preoperative...
|
|
|
Advances in HER2-positive breast cancer: An interview with Eric P. Winer, MD
Eric P.Winer, MD Reporting from the MBCC, ONCOLOGY spoke with Eric P. Winer, MD, Director, Breast Oncology Center; Chief, Division of Women's Cancers; Thompson Senior Investigator in Breast Cancer Research, Dana-Farber Cancer Institute. At this years...
|
|
|
Phase III study of Avastin in advanced stomach cancer did not meet primary endpoint
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with...
|
|
|
Roche, Genentech report Avastin study failure
NEW YORK - Genentech said Tuesday the combination of its blockbuster cancer drug Avastin and Xeloda did not meet a late-stage study goal of extending the lives of advanced stomach cancer patients.The company, a unit of Switzerland's Roche, said it will...
|
|
|
The 27th Annual Miami Breast Cancer Conference (MBCC)
Reporting from the MBCC, ONCOLOGY spoke with Eric P.Winer, MD, Director, Breast Oncology Center; Chief, Division of Women's Cancers; Thompson Senior Investigator in Breast Cancer Research, Dana-Farber Cancer Institute. At this years conference, Dr. Winer...
|
|
|
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin (bevacizumab) plus Xeloda (capecitabine) or 5-FU and cisplatin...
|
|
|
Avastin Fails to Prolong Survival in Stomach Cancer
Avastin (bevacizumab) in combination with chemotherapy does not extend overall survival in patients with inoperable, advanced or metastatic stomach cancer, according to the results of a phase III trial released by Roche.[i] Stomach cancer, also known as gastric...
|
|
|
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Adverse events in the trial were consistent with those previously reported for Avastin and no new safety signals have been observed to date.Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual...
|
|
|
Roche cancer drug Xeloda gets new EU recommendation - Reuters
_ Roche cancer drug Xeloda gets new EU recommendation - Reuters.
|
|
|
UPDATE 1-Roche cancer drug Xeloda gets new EU recommendation
* European Agency gives positive opinion on new Xeloda-use * Drug already approved in wide range of treatments ZURICH, Feb 24 (Reuters) - Swiss drugmaker Roche Holding AG's <ROG.VX> blockbuster cancer drug Xeloda received a European Union...
|
|
|
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Let the jobs come to you!Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin (bevacizumab) plus Xeloda ...
|
|
|
Phase III Study Of Avastin Plus Chemotherapy In Advanced Stomach Cancer Did Not Meet Primary Endpoint
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin (bevacizumab) plus Xeloda (capecitabine) or 5-FU and cisplatin...
|
|
|
Feb 22, 2010
-- Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin (bevacizumab) plus Xeloda (capecitabine) or 5-FU and cisplatin...
|
|
|
UPDATE 1-Roche cancer drug Xeloda gets new EU recommendation
* European Agency gives positive opinion on new Xeloda-use * Drug already approved in wide range of treatments ZURICH, Feb 24 (Reuters) - Swiss drugmaker Roche Holding AG's (ROG.VX The Committee on Human Medicinal Products (CHMP) recommended Xeloda...
|
|
|
UPDATE 1-Roche cancer drug Xeloda gets new EU recommendation
ZURICH, Feb 24 (Reuters) - Swiss drugmaker Roche Holding AG's blockbuster cancer drug Xeloda received a European Union recommendation for a treatment of early colon cancer.The Committee on Human Medicinal Products (CHMP) recommended Xeloda in...
|
|
|
Cancer drug Xeloda gets EU backing
The European Union has recommended Xeloda be used to treat early colon cancer.Patients should be treated with the drug, manufactured by Roche Holding AG, alongside oxaliplatin (Eloxatin), following surgery for the cancer, an EU committee recommended.
|
